Safety Profile
Known Safety Concerns
- Theoretical bacteremia risk in immunocompromised patients
- Heterofermentative -- trace ethanol production
- Immune stimulation concerns in autoimmune disease
Contraindications
- Theoretical bacteremia risk in immunocompromised patients
- Heterofermentative -- trace ethanol production
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Lactobacillus fermentum is used for gut health, immune modulation, and cholesterol management. Heterofermentative — produces CO2 and ethanol in addition to lactic acid. Generally safe.
Biological and Chemical Classification
- Scientific Name
- Lactobacillus fermentum (Limosilactobacillus fermentum)
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Probiotic
- Evidence consistency: High consistency across studies (100%)
- Theoretical bacteremia risk in immunocompromised patients
- Heterofermentative -- trace ethanol production
- Immune stimulation concerns in autoimmune disease
The available scientific evidence for Lactobacillus Fermentum indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 29 აპრ 2026, 10:46
Evidence Distribution
-
Observational / other LOW evidence YELLOWA colon mimetic screening approach reveals Lactobacillus fermentum as a microbiome-based therapy for COPD. ↗Kim NH et al.. A colon mimetic screening approach reveals Lactobacillus fermentum as a microbiome-based therapy for COPD.. NPJ Biofilms Microbiomes. 2026. PMID:41980958.PMID 41980958 ↗Journal NPJ Biofilms MicrobiomesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41980958/
-
Observational / other LOW evidence YELLOWOptimization and chemical modification of exopolysaccharides from lactic acid bacteria: multi-functional health-promoting properties and structure-activity relationship. ↗Hu T et al.. Optimization and chemical modification of exopolysaccharides from lactic acid bacteria: multi-functional health-promoting properties and structure-activity relationship.. Arch Microbiol. 2026. PMID:41910725.PMID 41910725 ↗Journal Arch MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41910725/
-
Observational / other LOW evidence YELLOWEffects of a Compound Probiotic on Production Performance, Intestinal Health, Immune Function, and Gut Microbiota in Broiler Chickens. ↗Liu Y et al.. Effects of a Compound Probiotic on Production Performance, Intestinal Health, Immune Function, and Gut Microbiota in Broiler Chickens.. Vet Sci. 2026. PMID:41893644.PMID 41893644 ↗Journal Vet SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41893644/
-
Observational / other LOW evidence YELLOWRecent advances on fermentation of mustard plant (Brassica juncea L.): microbial community, fermentation processing and sensorial quality: a review. ↗Diao N et al.. Recent advances on fermentation of mustard plant (Brassica juncea L.): microbial community, fermentation processing and sensorial quality: a review.. Front Microbiol. 2026. PMID:41883800.PMID 41883800 ↗Journal Front MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41883800/
-
Observational / other LOW evidence YELLOWLactobacillus probiotics attenuate hyperlipidemia and fatty liver in rat via LPS and 5-HT-related signaling axis. ↗Zhang S et al.. Lactobacillus probiotics attenuate hyperlipidemia and fatty liver in rat via LPS and 5-HT-related signaling axis.. Future Microbiol. 2026. PMID:41841685.PMID 41841685 ↗Journal Future MicrobiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41841685/
-
Observational / other LOW evidence YELLOWEfficient d-Galactose Conversion and Functional Rare Sugar Production via Scaffold-Based Enzyme Complex Platforms. ↗Song SM et al.. Efficient d-Galactose Conversion and Functional Rare Sugar Production via Scaffold-Based Enzyme Complex Platforms.. J Agric Food Chem. 2026. PMID:41841370.PMID 41841370 ↗Journal J Agric Food ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41841370/
-
Observational / other LOW evidence YELLOWBiogenic synthesis of zinc nanoparticles by exopolysaccharide from Lactobacillus fermentum. ↗de Carvalho L et al.. Biogenic synthesis of zinc nanoparticles by exopolysaccharide from Lactobacillus fermentum.. Food Sci Technol Int. 2026. PMID:41761699.PMID 41761699 ↗Journal Food Sci Technol IntYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41761699/
-
Observational / other LOW evidence YELLOWLactobacillus fermentum supplementation modulates jejunal microbiota, metabolome, and morphology in yaks under high-energy feeding. ↗Yu Q et al.. Lactobacillus fermentum supplementation modulates jejunal microbiota, metabolome, and morphology in yaks under high-energy feeding.. Anim Microbiome. 2026. PMID:41680945.PMID 41680945 ↗Journal Anim MicrobiomeYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41680945/
-
Observational / other LOW evidence YELLOWCorrigendum to "Ganoderma lucidum dietary fiber and lactobacillus fermentum CECT5716 alleviate constipation via regulation of gut barrier and microbiota" [Int. J. Biol.… ↗Wang C et al.. Corrigendum to "Ganoderma lucidum dietary fiber and lactobacillus fermentum CECT5716 alleviate constipation via regulation of gut barrier and microbiota" [Int. J. Biol. Macromol. 333 (2025) 149010].. Int J Biol Macromol. 2026. PMID:41667327.PMID 41667327 ↗Journal Int J Biol MacromolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41667327/
-
Observational / other LOW evidence YELLOWEffects of Supplemental Effective Microorganisms in Feed on the Growth, Lipid Deposition and GH-IGF-I Axis of the Blunt Snout Bream Megalobrama amblycephala. ↗Zhu H et al.. Effects of Supplemental Effective Microorganisms in Feed on the Growth, Lipid Deposition and GH-IGF-I Axis of the Blunt Snout Bream Megalobrama amblycephala.. Aquac Nutr. 2026. PMID:41658441.PMID 41658441 ↗Journal Aquac NutrYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41658441/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Lactobacillus Fermentum. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Lactobacillus Fermentum
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.